HER2-positive Gastric Cancer Clinical Trials

10 recruiting

HER2-positive Gastric Cancer Trials at a Glance

10 actively recruiting trials for her2-positive gastric cancer are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Fuzhou, Hangzhou, and Beijing. Lead sponsors running her2-positive gastric cancer studies include Daiichi Sankyo, Gruppo Oncologico del Nord-Ovest, and AstraZeneca.

Browse her2-positive gastric cancer trials by phase

Treatments under study

About HER2-positive Gastric Cancer Clinical Trials

Looking for clinical trials for HER2-positive Gastric Cancer? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2-positive Gastric Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2-positive Gastric Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled286 locationsNCT06764875
Recruiting
Phase 3

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006
Recruiting
Phase 1Phase 2

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer

Gastric (Stomach) CancerGastric AdenocarcinomaGEJ Adenocarcinoma+1 more
Henan Cancer Hospital45 enrolled1 locationNCT07334431
Recruiting
Phase 1

HER-2 B Cell Peptide Vaccine

Metastatic Breast CancerHER2-positive Breast CancerMetastatic Gastrointestinal Carcinoma+2 more
Pravin T.P Kaumaya42 enrolled1 locationNCT06414733
Recruiting
Phase 1

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

HER2-positive Breast CancerHER2-positive Colorectal CancerHER2-positive Gastric Cancer+2 more
Mersana Therapeutics162 enrolled14 locationsNCT05514717
Recruiting

Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China

HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction
Daiichi Sankyo260 enrolled36 locationsNCT06846996
Recruiting
Phase 2

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Metastatic Gastric CancerUnresectable Gastric CarcinomaHER2-positive Gastric Cancer
Qilu Hospital of Shandong University110 enrolled20 locationsNCT06730373
Recruiting
Phase 2

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

HER2-positive Gastric CancerAdenocarcinoma of the StomachAdenocarcinoma of Esophagogastric Junction
Yu jiren30 enrolled8 locationsNCT05715931
Recruiting
Phase 1Phase 2

Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens

HER2-positive Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Zhejiang Cancer Hospital35 enrolled1 locationNCT06572319
Recruiting
Phase 2

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

Gastric CancerHER2-positive Gastric Cancer
Gruppo Oncologico del Nord-Ovest46 enrolled1 locationNCT06253650